Cargando…
PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse
BACKGROUND: Advanced ovarian cancer is characterized by peritoneal metastasis and the accumulation of ascites. Peritoneal metastasis of ovarian cancer is a major cause of the negative treatment outcome, as these metastases are resistant to most chemotherapy regimens. The aim of this study was to cla...
Autores principales: | Konishi, Hiroaki, Takagi, Akimitsu, Kurita, Akinobu, Kaneda, Norimasa, Matsuzaki, Takeshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523201/ https://www.ncbi.nlm.nih.gov/pubmed/23046546 http://dx.doi.org/10.1186/1471-2407-12-462 |
Ejemplares similares
-
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
por: Wu, Huali, et al.
Publicado: (2015) -
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]
Publicado: (2019) -
Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006) -
Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009) -
Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010)